Tania Schink, n/a

Leibniz Institute for Prevention Research and Epidemiology – BIPS GmbH, Germany

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Poster(s):

• (P-065) Safety of Rivaroxaban in First-time Users Treated for Deep Vein Thrombosis and Pulmonary Embolism

• (P-071) Inception to Conception: A Conceptual Framework for Characterizing Pharmacoepidemiologic Data Sources. a Study from the Conception Project

• (P-250) Lessons from a Post-authorisation Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Practice in Four Countries

• (P-252) Safety and Effectiveness of Rivaroxaban in First-time Users with Non-valvular Atrial Fibrillation in Routine Practice

• (P-314) Time Trends in Patient Characteristics of New Rivaroxaban (RVX) Users with Atrial Fibrillation (AF) Across Four Countries